Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily

Claus G Roehrborn1, Raymond C Rosen21Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA; 2New England Research Institutes, Watertown, MA, USAAbstract: Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) are common in ag...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Claus G Roehrborn, Raymond C Rosen
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	alfuzosin lower urinary tract symptoms benign prostatic hyperplasia aging cardiovascular system sexual function Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/3c62a8f7c5e74916b124a7f817463211
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3c62a8f7c5e74916b124a7f817463211
record_format	dspace
spelling	oai:doaj.org-article:3c62a8f7c5e74916b124a7f8174632112021-12-02T02:08:00ZMedical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily1178-1998https://doaj.org/article/3c62a8f7c5e74916b124a7f8174632112008-09-01T00:00:00Zhttps://www.dovepress.com/medical-therapy-options-for-aging-men-with-benign-prostatic-hyperplasi-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Claus G Roehrborn1, Raymond C Rosen21Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA; 2New England Research Institutes, Watertown, MA, USAAbstract: Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) are common in aging men and can significantly affect quality of life. Men with bothersome LUTS/BPH often present with various other age-related conditions, including sexual dysfunction, heart disease, hypertension, diabetes, and the metabolic syndrome, which can complicate management decisions. Therefore, healthcare providers should be familiar with first-line treatment options for LUTS/BPH and their differing safety profiles, particularly with respect to cardiovascular and sexual function side effects. This article presents a review of first-line medical therapy options for managing aging men with LUTS/BPH and patient considerations when evaluating and selecting these therapies, with a focus on the clinical efficacy and cardiovascular and sexual function safety profiles of the uroselective α1-adrenergic receptor antagonist alfuzosin 10 mg once daily. Alfuzosin improves LUTS, peak urinary flow rates, and disease-specific quality of life, reduces the long-term risk of overall BPH progression, and is well tolerated in aging men, with minimal vasodilatory and sexual function side effects, even in those with comorbidities. Alfuzosin is well tolerated when used in combination with antihypertensive medications and phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. The long-term clinical efficacy and good cardiovascular and sexual function safety profile of alfuzosin can contribute to an improved quality of life for aging men with LUTS/BPH.Keywords: alfuzosin, lower urinary tract symptoms, benign prostatic hyperplasia, aging, cardiovascular system, sexual functionClaus G RoehrbornRaymond C RosenDove Medical Pressarticlealfuzosinlower urinary tract symptomsbenign prostatic hyperplasiaagingcardiovascular systemsexual functionGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 3, Pp 511-524 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	alfuzosin lower urinary tract symptoms benign prostatic hyperplasia aging cardiovascular system sexual function Geriatrics RC952-954.6
spellingShingle	alfuzosin lower urinary tract symptoms benign prostatic hyperplasia aging cardiovascular system sexual function Geriatrics RC952-954.6 Claus G Roehrborn Raymond C Rosen Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
description	Claus G Roehrborn1, Raymond C Rosen21Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA; 2New England Research Institutes, Watertown, MA, USAAbstract: Lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) are common in aging men and can significantly affect quality of life. Men with bothersome LUTS/BPH often present with various other age-related conditions, including sexual dysfunction, heart disease, hypertension, diabetes, and the metabolic syndrome, which can complicate management decisions. Therefore, healthcare providers should be familiar with first-line treatment options for LUTS/BPH and their differing safety profiles, particularly with respect to cardiovascular and sexual function side effects. This article presents a review of first-line medical therapy options for managing aging men with LUTS/BPH and patient considerations when evaluating and selecting these therapies, with a focus on the clinical efficacy and cardiovascular and sexual function safety profiles of the uroselective α1-adrenergic receptor antagonist alfuzosin 10 mg once daily. Alfuzosin improves LUTS, peak urinary flow rates, and disease-specific quality of life, reduces the long-term risk of overall BPH progression, and is well tolerated in aging men, with minimal vasodilatory and sexual function side effects, even in those with comorbidities. Alfuzosin is well tolerated when used in combination with antihypertensive medications and phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction. The long-term clinical efficacy and good cardiovascular and sexual function safety profile of alfuzosin can contribute to an improved quality of life for aging men with LUTS/BPH.Keywords: alfuzosin, lower urinary tract symptoms, benign prostatic hyperplasia, aging, cardiovascular system, sexual function
format	article
author	Claus G Roehrborn Raymond C Rosen
author_facet	Claus G Roehrborn Raymond C Rosen
author_sort	Claus G Roehrborn
title	Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
title_short	Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
title_full	Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
title_fullStr	Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
title_full_unstemmed	Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
title_sort	medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/3c62a8f7c5e74916b124a7f817463211
work_keys_str_mv	AT clausgroehrborn medicaltherapyoptionsforagingmenwithbenignprostatichyperplasiafocusonalfuzosin10mgoncedaily AT raymondcrosen medicaltherapyoptionsforagingmenwithbenignprostatichyperplasiafocusonalfuzosin10mgoncedaily
_version_	1718402643152338944

Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily

Ejemplares similares